Literature DB >> 1728195

Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.

J Delabie1, E Vandenberghe, C Kennes, G Verhoef, M P Foschini, M Stul, J J Cassiman, C De Wolf-Peeters.   

Abstract

This study reports six non-Hodgkin's lymphoma cases that we called histiocyte-rich B-cell lymphoma (BCL) because of the prominent reactive histiocytic infiltrate obscuring the malignant B-cell population. The involved lymph nodes are characterized by a mixed nodular and diffuse infiltrate and occasionally feature prominent sinuses. The infiltrate is composed of reactive lymphocytes and numerous histiocytes obscuring a tumor population composed of variably sized scattered cells with irregular or multilobar vesicular nuclei. Immunostaining of paraffin sections for the B-cell marker recognized by L26 helps in the identification of these neoplastic cells. The clonal nature and further evidence of the B-cell lineage of this condition is shown by immunoglobulin gene rearrangements detected in three cases. The six cases of histiocyte-rich BCL are remarkably similar clinically: all presented with stage IVB disease with splenomegaly and follow an aggressive clinical course. Except for these features, our series show striking similarities to paragranuloma lymphocyte-predominant Hodgkin's disease, including male preponderance (all patients are male), age distribution (mean age, 41 years), propensity to progress to a diffuse, large B-cell lymphoma (two cases), as well as morphology of the neoplastic B-cell population and expression of Hodgkin's cell markers (Leu-M1 positivity after neuraminidase digestion in three cases, Leu-M1 positivity without neuraminidase digestion in one case, and additional epithelial membrane antigen [EMA] positivity in two cases). Both morphologically and clinically, the present series can be differentiated from other types of infiltrate-rich BCL, such as T-cell-rich BCL. Although additional cases will have to be recognized, histiocyte-rich B-cell lymphoma most likely represents a distinct clinicopathological entity. We speculate that it develops from a subset of B cells that also gives rise to the lymphocytic-histiocytic (L/H) cell, the Hodgkin's cell variant of lymphocyte-predominant Hodgkin's disease, paragranuloma subtype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1728195

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  17 in total

1.  Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma.

Authors:  Sabine Franke; Iwona Wlodarska; Brigitte Maes; Peter Vandenberghe; Ruth Achten; Anne Hagemeijer; Chris De Wolf-Peeters
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments.

Authors:  Cigdem Atayar; Anke van den Berg; Tjasso Blokzijl; Marcel Boot; Randy D Gascoyne; Lydia Visser; Sibrand Poppema
Journal:  J Clin Pathol       Date:  2006-12-08       Impact factor: 3.411

3.  T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Stefania Pittaluga; Elaine S Jaffe
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

4.  Morphological variability of tumour cells in T-cell-rich B-cell lymphoma. A histopathological study of 14 cases.

Authors:  S Camilleri-Bröet; T Molina; J Audouin; A L Tourneau; J Diebold
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

5.  Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.

Authors:  L Flenghi; B Bigerna; M Fizzotti; S Venturi; L Pasqualucci; S Pileri; B H Ye; M Gambacorta; R Pacini; C D Baroni; E Pescarmona; I Anagnostopoulos; H Stein; G Asdrubali; M F Martelli; P G Pelicci; R Dalla-Favera; B Falini
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

6.  Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.

Authors:  Thomas A Ollila; John L Reagan; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2019-07-09

7.  A 26-year-old man with Hodgkin's disease and rapidly progressive pancytopenia.

Authors:  J C Kluin-Nelemans; P M Kluin; R Bieger
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

Review 8.  T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification.

Authors:  Thomas Tousseyn; Christiane De Wolf-Peeters
Journal:  Virchows Arch       Date:  2011-11-12       Impact factor: 4.064

9.  T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas.

Authors:  R E Felgar; K R Steward; J B Cousar; W R Macon
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Histiocytic and t-cell rich b-cell lymphoma (TCRBCL) of the stomach.

Authors:  J Tóth; G Elek
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.